Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
Pediatric Blood & Cancer|August 11, 2020
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional studyJohannes Oldenburg, Midori Shima, Rebecca Kruse-Jarres, et al.
The Journal of Clinical Psychiatry|September 1, 2017
The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive DisorderRoger S McIntyre, Michael W Best, Christopher R Bowie, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 25, 2019
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS)Johnny Mahlangu, Johannes Oldenburg, Michael U Callaghan, et al.
Research and Practice in Thrombosis and Haemostasis|September 29, 2022
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3Michael U Callaghan, Elina Asikanius, Michaela Lehle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 15, 2018
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 StudyJohannes Oldenburg, Johnny N Mahlangu, Willem Bujan, et al.
Clinical Breast Cancer|June 3, 2025
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II StudyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
British Journal of Haematology|February 19, 2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN studyStephan Stilgenbauer, Francesc Bosch, Osman Ilhan, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
JAMA Oncology|September 10, 2016
Effect of a Patient-Centered Communication Intervention on Oncologist-Patient Communication, Quality of Life, and Health Care Utilization in Advanced Cancer: The VOICE Randomized Clinical TrialRonald M Epstein, Paul R Duberstein, Joshua J Fenton, et al.
Pageof 23